Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Severely Reduced Female Fertility in CD9-Deficient Mice
This map shows the geographic impact of C Jasmin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Jasmin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Jasmin more than expected).
This network shows the impact of papers produced by C Jasmin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Jasmin. The network helps show where C Jasmin may publish in the future.
Co-authorship network of co-authors of C Jasmin
This figure shows the co-authorship network connecting the top 25 collaborators of C Jasmin.
A scholar is included among the top collaborators of C Jasmin based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with C Jasmin. C Jasmin is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Fredj, G, et al.. (1989). Tetrahydroaminoacridine in HIV infections. The THA Study Group.. PubMed. 27(8). 408–10.1 indexed citations
13.
Jasmin, C. (1982). La petite patrie.2 indexed citations
14.
Mathé, G, J. L. Misset, F. de Vassal, et al.. (1978). Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.. PubMed. 62(5). 805–9.47 indexed citations
15.
Larnicol, Nicole, et al.. (1977). Effect of the nitrosourea derivative rpcnu (ICIG 1163) on the development of Friend leukemia in mice.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 26(3). 176–81.3 indexed citations
16.
Amiel, Jeanne, L Schwarzenberg, P Pouillart, et al.. (1975). Immunothérapie active des leucémies aiguës et des lymphosarcomes leucémiques. Bilar de 10 ans-Etude de 200 cas. La Nouvelle presse médicale. 4(18).3 indexed citations
17.
Jl, Misset, P Pouillart, Amiel Jl, et al.. (1975). [Adriamycin, VM 26, cyclophosphamide and prednisone (AVmCP) combination in the therapy of disseminated lymphoreticulosarcoma (Stages or topographical forms III and IV].. PubMed. 4(44). 3117–20.1 indexed citations
18.
Schwarzenberg, L, et al.. (1968). Haute fréquence et qualité des rémissions de la leucémie aiguü lymphoblastique chez l'enfant. Induites par l'association de data-1-cortisone, leurocristine et rubidomycine. Intérêt des chambres exemptes de germes pathogènes.. 25(2).2 indexed citations
19.
Jasmin, C, et al.. (1968). Action de l'actinomycine D sur la maladie de Friend.. 13(3).1 indexed citations
20.
Mathé, G, Jeanne Amiel, L Schwarzenberg, et al.. (1968). Greffe de moelle osseuse allogénique chez l'hormme provée par six marqueurs antigéniques après conditionnnement du receveur et du donneur par le sérum antilymphocytaire.. 13(10).3 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.